Soft Tissue Sarcoma - Pipeline Review, H2 2015 Now Available at iData Insights Soft Tissue Sarcoma - Pipeline Review, H2 2015 Summary Global Markets Direct s, Soft Tissue Sarcoma Pipeline Review, H2 2015, provides an overview of the Soft Tissue Sarcomas therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Soft Tissue Sarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Soft Tissue Sarcoma and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Soft Tissue Sarcoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities The report reviews key players involved in the therapeutics development for Soft Tissue Sarcoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Soft Tissue Sarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Soft Tissue Sarcoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies Identify and understand important and diverse types of therapeutics under development for Soft Tissue Sarcoma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Soft Tissue Sarcoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand
1
business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. with TOC @ http://www.idatainsights.com/reports-landing-page.php?id=173360/soft-tissuesarcoma-pipeline-review-h2-2015
Browse
To Get Sample Copy of Report visit @ http://www.idatainsights.com/reports-landingpage.php?id=173360/soft-tissue-sarcoma-pipeline-review-h2-2015 Table of Contents
Introduction 9 Global Markets Direct Report Coverage 9 Soft Tissue Sarcoma Overview 10 Therapeutics Development 11 Pipeline Products for Soft Tissue Sarcoma - Overview 11 Pipeline Products for Soft Tissue Sarcoma - Comparative Analysis 12 Soft Tissue Sarcoma - Therapeutics under Development by Companies 13 Soft Tissue Sarcoma - Therapeutics under Investigation by Universities/Institutes 18 Soft Tissue Sarcoma - Pipeline Products Glance 19 Late Stage Products 19 Clinical Stage Products 20 Early Stage Products 21 Unknown Stage Products 22 Soft Tissue Sarcoma - Products under Development by Companies 23 Soft Tissue Sarcoma - Products under Investigation by Universities/Institutes 29 Soft Tissue Sarcoma - Companies Involved in Therapeutics Development 30 A. Menarini Industrie Farmaceutiche Riunite Srl 30 Advanced Proteome Therapeutics Corporation 31 Advenchen Laboratories, LLC 32 Altor BioScience Corporation 33 Amgen Inc. 34 2
Arog Pharmaceuticals, Inc. 35 Bayer AG 36 Bellicum Pharmaceuticals, Inc. 37 Boehringer Ingelheim GmbH 38 CASI Pharmaceuticals Inc. 39 Celgene Corporation 40 Cell Medica Limited 41 Cellceutix Corporation 42 Cellectar Biosciences, Inc. 43 CytRx Corporation 44 Daiichi Sankyo Company, Limited 45 Double Bond Pharmaceutical International AB 46 Eisai Co., Ltd. 47 Eli Lilly and Company 48 EpiZyme, Inc. 49 Exelixis, Inc. 50 F. Hoffmann-La Roche Ltd. 51 Gem Pharmaceuticals, LLC 52 GlaxoSmithKline Plc 53 Immune Design Corp. 54 Karyopharm Therapeutics, Inc. 55 Loxo Oncology, Inc. 56 Lytix Biopharma AS 57 MedImmune, LLC 58 Merck & Co., Inc. 59 Merrimack Pharmaceuticals, Inc. 60
3
Mirati Therapeutics Inc. 61 MolMed S.p.A. 62 Morphotek, Inc. 63 Northwest Biotherapeutics, Inc. 64 Novartis AG 65 Noxxon Pharma AG 66 OncoTherapy Science, Inc. 67 Onxeo SA 68 Pfizer Inc. 69 Pharma Mar, S.A. 70 Philogen S.p.A. 71 Plexxikon Inc. 72 Polaris Pharmaceuticals, Inc. 73 Recombio S.L 74 Rigontec GmbH 75 Sanofi 76 Shionogi & Co., Ltd. 77 Siena Biotech S.p.A. 78 Sigma-Tau S.p.A. 79 Sumitomo Dainippon Pharma Co., Ltd. 80 Targovax AS 81 Threshold Pharmaceuticals, Inc. 82 TRACON Pharmaceuticals, Inc. 83 Vicore Pharma AB 84 Soft Tissue Sarcoma - Therapeutics Assessment 85 Assessment by Monotherapy Products 85 Assessment by Combination Products 86 4
Assessment by Target 87 Assessment by Mechanism of Action 94 Assessment by Route of Administration 99 Assessment by Molecule Type 101 Drug Profiles 103 afatinib dimaleate - Drug Profile 103 AL-3818 - Drug Profile 108 aldoxorubicin hydrochloride - Drug Profile 110 ALT-836 - Drug Profile 113 APC-103 - Drug Profile 115 belinostat - Drug Profile 116 BI-853520 - Drug Profile 119 C-21 - Drug Profile 120 cabazitaxel - Drug Profile 122 cabozantinib s-malate - Drug Profile 124 cancer vaccine - Drug Profile 128 Cell Therapy to Target LMP-1 and LMP-2 for Oncology and Infectious Diseases - Drug Profile 129 Cellular Immunotherapy for GD2 Expressing Solid Tumors - Drug Profile 130 celyvir - Drug Profile 132 CMD-003 - Drug Profile 134 crenolanib besylate - Drug Profile 136 DCVax-Direct - Drug Profile 138 Dendritic Cell Therapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile 139 Dendritic Cells + Cytokine Induced Killer Cells - Drug Profile 140 DSR-6434 - Drug Profile 141 durvalumab + tremelimumab - Drug Profile 142
5
efatutazone - Drug Profile 144 emactuzumab - Drug Profile 146 ENMD-2076 - Drug Profile 147 eribulin mesylate - Drug Profile 149 everolimus - Drug Profile 155 evofosfamide - Drug Profile 161 Fibromun - Drug Profile 169 G-100 - Drug Profile 171 GPX-150 - Drug Profile 173 GSK-3174998 - Drug Profile 176 HDM-201 - Drug Profile 177 I131-CLR1404 - Drug Profile 178 ID-LV305 + ID-G305 - Drug Profile 180 ImOl-100 - Drug Profile 182 irinotecan hydrochloride - Drug Profile 183 KM-3174 - Drug Profile 186 KRA-0008 - Drug Profile 190 LK-3 - Drug Profile 191 LOXO-101 - Drug Profile 192 LTX-315 - Drug Profile 194 LV-305 - Drug Profile 196 MAT-303 - Drug Profile 197 mocetinostat - Drug Profile 198 MVXONCO-1 - Drug Profile 201 NGR-hTNF - Drug Profile 202 NOV-110501 - Drug Profile 206 NOXS-93 - Drug Profile 207 6
olaratumab - Drug Profile 208 ONCOS-102 - Drug Profile 211 ontuxizumab - Drug Profile 213 OTSA-101 - Drug Profile 215 paclitaxel albumin bound - Drug Profile 216 palbociclib - Drug Profile 220 panobinostat - Drug Profile 224 pazopanib hydrochloride - Drug Profile 230 pembrolizumab - Drug Profile 236 Peptide to Target COX-2 and MAS-GPCR for Oncology - Drug Profile 245 PF-03084014 - Drug Profile 247 PLX-7486 - Drug Profile 249 regorafenib - Drug Profile 250 ribociclib - Drug Profile 254 roneparstat - Drug Profile 257 S-588410 - Drug Profile 258 SA-083 - Drug Profile 259 sabarubicin - Drug Profile 260 selinexor - Drug Profile 262 SEN-461 - Drug Profile 268 talimogene laherparepvec - Drug Profile 269 tazemetostat - Drug Profile 272 TNF-PEG 20 - Drug Profile 274 trabectedin - Drug Profile 275 TRC-105 - Drug Profile 280 Vaccine for Soft Tissue Sarcoma - Drug Profile 283
7
vorinostat - Drug Profile 284 Soft Tissue Sarcoma - Recent Pipeline Updates 288 Soft Tissue Sarcoma - Dormant Projects 449 Soft Tissue Sarcoma - Discontinued Products 453 Soft Tissue Sarcoma - Product Development Milestones 454 Featured News & Press Releases 454 Appendix 463 Methodology 463 Coverage 463 Secondary Research 463 Primary Research 463 Expert Panel Validation 463 Contact Us 463 Disclaimer 464
Read More http://www.idatainsights.com/reports-landing-page.php?id=173360/soft-tissuesarcoma-pipeline-review-h2-2015 About Us: iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line. ContactUs: iData Insights Tel: 1-866-237-2965 Web: http://www.idatainsights.com Email: info@idatainsights.com About iData Insights
8
We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future projects
9